BioSpace News Archive

EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.

CASI Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, proudly announced the administration of the first dose of FOLOTYN® to a patient in China.

BioLineRx Ltd. announced that new post-hoc subgroup analyses and pharmacodynamic data will be presented on APHEXDA® for CD34+ hematopoietic stem cell mobilization in patients with multiple myeloma at the 2024 Tandem Meetings.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced the U.S. Food and Drug Administration has accepted and filed the Company’s efficacy supplement to the Biologics License Application for ELEVIDYS .

Y-mAbs Therapeutics, Inc. announced that it will report its financial results for the quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, after the close of the U.S. financial markets.

XOMA Corporation announced it has entered an agreement to acquire Kinnate Biopharma Inc. for a base cash price of $2.3352 per share and an additional cash amount of not more than $0.2527 per share at the closing of the merger plus a non-transferable contingent value right.

For the 11th consecutive year, Thermo Fisher Scientific’s pharma and biopharma customers recognized its contract manufacturing excellence through the annual CDMO Leadership awards sponsored by Outsourced Pharma and Life Science Connect.

Fusion Pharmaceuticals Inc. announced that it has entered into an exclusive worldwide license agreement with Heidelberg University and Euratom represented by the European Commission, Joint Research Centre.

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Xolair® for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.